Equity Research firms currently have a positive stance on shares of Rexahn Pharmaceuticals, Inc. (:RNN). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $2.00 on a short term basis.
At the time of writing, the stock was trading at $0.21. This represents a change from the opening price of -0.84%. In terms of performance, year to date, the stock is -41.27%. The monthly stock performance comes in at -14.92%. For the quarter, shares are performing at -16.23%. Weekly performance analysis shows the equity at -0.61%.
In taking a look at technical levels, shares are trading -13.27% away from the 50 day simple moving average and -28.30% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -59.00% away from it’s 52- week high and 5.75% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Rexahn Pharmaceuticals, Inc.’s RSI stands at 35.22. In looking at volatility levels, the shares saw weekly volatility of 4.43% and 5.67% over the past month.